Kairos Pharma Ltd. (NYSE American: KAPA) announced a strategic collaboration with Bayer to evaluate its lead antibody candidate, ENV-105 (carotuximab), in combination with Bayer’s XOFIGO (radium-223 dichloride) for the treatment of metastatic castration-resistant prostate cancer (mCRPC) involving bone. This partnership aims to address a critical unmet need in advanced prostate cancer by targeting treatment resistance.
ENV-105 is a first-in-class CD105/BMP signaling inhibitor designed to overcome cancer drug resistance. It is currently being evaluated in Phase 1 and Phase 2 clinical trials. Interim Phase 2 data previously reported by the company showed median progression-free survival of more than 13 months in prostate cancer patients. XOFIGO is the only FDA-approved alpha-emitting radiopharmaceutical for symptomatic bone metastases in this patient population.
The collaboration will investigate whether ENV-105 can enhance and extend responses to XOFIGO by targeting CD105, a protein associated with treatment resistance following androgen receptor inhibition and radiation therapy. Preclinical studies have demonstrated ENV-105’s ability to re-sensitize tumors to radiation, and management believes combining the therapy with XOFIGO could provide a more durable treatment option for patients with advanced prostate cancer.
This news matters because prostate cancer is one of the most common cancers in men, and metastatic castration-resistant prostate cancer with bone metastases has limited treatment options. The potential to overcome drug resistance and improve outcomes could significantly impact patients, the oncology field, and the pharmaceutical industry. If successful, this combination therapy could set a new standard of care for this difficult-to-treat condition.
Kairos Pharma, based in Los Angeles, California, focuses on oncology therapeutics using structural biology to address drug resistance and immune suppression. ENV-105 targets CD105, a key driver of resistance and disease relapse in response to standard therapy. The antibody aims to reverse drug resistance and restore the effectiveness of standard therapies across multiple cancer types. Currently, ENV-105 is in a Phase 2 trial for castrate-resistant prostate cancer and a Phase 1 trial for non-small cell lung cancer. As of the date of this press release, ENV-105 has not been approved as safe or effective by the United States Food and Drug Administration or any other comparable foreign regulator.
For more information, refer to the full press release at https://ibn.fm/emSc4. The latest news and updates relating to KAPA are available at https://ibn.fm/KAPA.
